News MedicalStudy Shows How Prostate Tumors Rewire Metabolism to Resist Therapy

⚠️ Early Stage / Preclinical Research

Investigators from Weill Cornell Medicine reported that prostate cancer cells may exploit branched-chain amino acid metabolism to maintain cholesterol synthesis despite androgen deprivation. The study identified propionyl-CoA, a metabolite generated from isoleucine and valine breakdown, as a signaling molecule that stabilizes SREBP2, a key regulator of cholesterol-producing genes.

Elevated activity of this pathway appeared to support ongoing androgen production within tumor cells, potentially helping maintain androgen receptor signaling despite treatment with androgen receptor-directed therapies such as enzalutamide.

Clinical Considerations

• Propionyl-CoA promoted SREBP2 propionylation, allowing cholesterol synthesis pathways to remain active under conditions that would normally suppress them.
• Investigators observed higher levels of propionylcarnitine, a related metabolite, in more aggressive human prostate tumors.
• In laboratory models, androgen deprivation increased propionyl-CoA production, suggesting a possible adaptive resistance mechanism.
• Mouse studies found dietary restriction of isoleucine and valine reduced tumor growth and lung metastases, while increasing propionyl-CoA promoted tumor progression.
• Authors suggest future exploration of metabolic enzyme inhibition, dietary modification, and potential interactions with statin responsiveness.

Practice Applications

• The findings provide mechanistic insight into how prostate tumors may adapt to androgen receptor blockade.
• No changes to clinical management, dietary counseling, or androgen receptor-targeted treatment strategies are supported by these data.
• Future clinical studies will be required to determine whether pathway activity can serve as a biomarker of resistance or predict response to adjunctive interventions such as statins.
• The work highlights a growing area of interest at the intersection of cancer metabolism and treatment resistance.